Hopefully we will get an announcement on the Stage 2 data - as flagged in several announcements.
However, based on the CEO's Half Yearly Update that the Keysight investment will 'support accelerating recruitment in our current multi-site trials' i.e. the pre-validation trials ('continuing Stage 2' and Stage 3), I wonder if they will wait until the pre-validation trial is complete or go ahead with providing a progress report on the original Stage 2 of 150 patients.
This is the relevant part of the Half Yearly Update:
"The investment will support accelerating recruitment in our current multi-site trials, the acquisition of comprehensive data sets during the upcoming clinical trial validation phase, which is essential for confirming the product's sensitivity and specificity in support of FDA approval and increasing the production of emu™ devices for targeted clinical trials at prestigious stroke centres in the United States, smoothing the pathway to commercialisation and adoption in the world's largest healthcare market"
Hopefully we will get an announcement on the Stage 2 data - as...
Add EMV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.10 |
Change
-0.050(2.33%) |
Mkt cap ! $179.3M | |||
| Open | High | Low | Value | Volume |
| $2.12 | $2.14 | $2.03 | $32.34K | 15.56K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | $2.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.10 | 9406 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.08 |
Change
-0.050 ( 0.61 %) |
||||
| Open | High | Low | Volume | ||
| $2.11 | $2.13 | $2.03 | 6767 | ||
| Last updated 15.42pm 03/05/2024 ? | |||||
| EMV (ASX) Chart |